China Sky One Medical, a leading fully integrated pharmaceutical company in China has announced that the Company, jointly with Heilongjiang Traditional Chinese Medical University (HTCMU), has obtained production licenses for thirteen new medical products from the Heilongjiang Food and Drug Administration in China. These thirteen products include Kang Xi Eye Patch, KangXi Dental Ulcer Membrane, KangXi Anti-virus Mouthwash, KangXi Dental Ulcer Mouthwash, KangXi Snore Stopper, Kang Xi Periarthritis Shoulder Patch, KangXi Cervical Vertebrae Patch, KangXi Lumbar Patch, KangXi Rheumatoid Patch, KangXi Hyperostosis Patch, BiChang Nose Patch,  YuFu Scar Patch,  YuFu Wound Healing Patch.

China Sky One is preparing for trial production and searching for the best production process for these thirteen products, which the Company expects to introduce to the market as soon as the fourth quarter of 2011.

"We are pleased to obtain production licenses for these exciting new products, which as a group we believe will contribute materially to China Sky One's revenue and net income in 2012," commented Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "As these mostly external-use medical products dovetail well with our existing production facilities and sales network, we expect to manufacture and sell them efficiently without much extra effort. Going forward, we plan to strengthen our partnership with research institutions such as HTCMU, leveraging their R&D capabilities to enrich our product portfolio and improve the Company's profitability."